Guanabenz Acetate

Catalog No.S4065 Synonyms: WY-8678 Acetate

For research use only.

Guanabenz Acetate (WY-8678) is an selective agonist of α2a-adrenergic receptor, α2b-adrenergic receptor and α2c-adrenergic receptor with pEC50 of 8.25, 7.01 and ~5, respectively.

Guanabenz Acetate Chemical Structure

CAS No. 23256-50-0

Selleck's Guanabenz Acetate has been cited by 2 Publications

Purity & Quality Control

Choose Selective Adrenergic Receptor Inhibitors

Other Adrenergic Receptor Products

Biological Activity

Description Guanabenz Acetate (WY-8678) is an selective agonist of α2a-adrenergic receptor, α2b-adrenergic receptor and α2c-adrenergic receptor with pEC50 of 8.25, 7.01 and ~5, respectively.
Targets
α2a-adrenergic receptor [1] α2b-adrenergic receptor [1] α2c-adrenergic receptor [1]
8.25(pEC50) 7.01(pEC50) <5(pEC50)
In vitro

Guanabenz at a concentration of 30 μM causes a time-dependent loss of nNOS-activity, which is present in cytosol prepared from rat nNOS transfected HEK 293 cells, with a Ki of 1 μM. Guanabenz can induce a concentration-dependent loss of nNOS activity. Within the first 3 h of treatment, 50 μM Guanabenz decreases the accumulation of nitrite and nitrate by approximately 75% in cells. Treatment of HEK 293 cells for 24 h with Guanabenz (100 μM) causes an approximately 35% decrease in the amount of immunodetectable nNOS protein. Guanabenz enhances proteolysis of the protein with the half-life decreasing by one-half from 20 to 10 h. [2] Guanabenz is active against [ PSI+] prion in the yeast-based assay independent of its agonist activity on α2-adrenergic receptors. Guanabenz (10 μM) promote complete PrPSc clearance in mammalian MovS6 cell-based assay. [3]

In vivo Guanabenz injected i.v. in doses of 0.1 mg/kg causes an initial increase in blood pressure followed by a prolonged fall and a decrease in cardiac output, contractile force and heart rate in anesthetized dogs, which requires the presence of sympathetic tone. Guanabenz inhibits pressor responses to various procedures which initiate general sympathetic discharge. Guanabenz also antagonizes responses to sympathetic nerve stimulation. [4] Guanabenz injected at doses of 0.5 mg/kg and above lowers blood pressure and heart rate in unanesthetized hypertensive rats and dogs. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 58 mg/mL
(199.22 mM)
Ethanol 5 mg/mL
(17.17 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.

5mg/mL

Chemical Information

Molecular Weight 291.13
Formula

C8H8Cl2N4.C2H4O2

CAS No. 23256-50-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)O.C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02423083 Terminated Drug: Guanabenz Multiple Sclerosis Relapsing-Remitting|Multiple Sclerosis National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) April 21 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Guanabenz Acetate | Guanabenz Acetate ic50 | Guanabenz Acetate price | Guanabenz Acetate cost | Guanabenz Acetate solubility dmso | Guanabenz Acetate purchase | Guanabenz Acetate manufacturer | Guanabenz Acetate research buy | Guanabenz Acetate order | Guanabenz Acetate mouse | Guanabenz Acetate chemical structure | Guanabenz Acetate mw | Guanabenz Acetate molecular weight | Guanabenz Acetate datasheet | Guanabenz Acetate supplier | Guanabenz Acetate in vitro | Guanabenz Acetate cell line | Guanabenz Acetate concentration | Guanabenz Acetate nmr